botulinum toxin type A (ABBV-950) / AbbVie - LARVOL DELTA

Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity (clinicaltrials.gov) - P1 | N=1 | Terminated | Sponsor: AbbVie | Phase classification: P1/2 ➔ P1 | N=297 ➔ 1 | Trial completion date: Nov 2026 ➔ Jun 2024 | Active, not recruiting ➔ Terminated | Trial primary completion date: Nov 2026 ➔ Jun 2024; Strategic considerations

Adverse events • Enrollment change • Phase classification • Trial completion date • Trial primary completion date • Trial termination • Cardiovascular • Movement Disorders

Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity (clinicaltrials.gov) - P1/2 | N=297 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting

Adverse events • Enrollment closed • Cardiovascular • Movement Disorders

Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity (clinicaltrials.gov) - P1/2 | N=297 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting | Initiation date: Sep 2023 ➔ Jan 2024

Adverse events • Enrollment open • Trial initiation date • Cardiovascular • Movement Disorders

Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity (clinicaltrials.gov) - P1/2 | N=297 | Not yet recruiting | Sponsor: AbbVie

Adverse events • New P1/2 trial • Cardiovascular • Movement Disorders